These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23700287)

  • 1. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
    Belum VR; Wu S; Lacouture ME
    Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
    Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
    Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
    Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
    McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
    Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
    Wang Z; Xu J; Nie W; Huang G; Tang J; Guan X
    Eur J Clin Pharmacol; 2014 Feb; 70(2):225-31. PubMed ID: 24150533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
    Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
    Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
    Balagula Y; Wu S; Su X; Feldman DR; Lacouture ME
    Invest New Drugs; 2012 Aug; 30(4):1773-81. PubMed ID: 21394443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
    Chu D; Lacouture ME; Fillos T; Wu S
    Acta Oncol; 2008; 47(2):176-86. PubMed ID: 18210295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.
    Ono K; Murase R; Matsumoto N; Kubota Y; Ishida H; Fujita KI
    Cancer Chemother Pharmacol; 2024 Jul; 94(1):57-66. PubMed ID: 38459188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
    Fischer A; Wu S; Ho AL; Lacouture ME
    Invest New Drugs; 2013 Jun; 31(3):787-97. PubMed ID: 23345001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.
    Yin X; Yin Y; Shen C; Chen H; Wang J; Cai Z; Chen Z; Zhang B
    Onco Targets Ther; 2018; 11():6405-6414. PubMed ID: 30323618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
    Chu D; Lacouture ME; Weiner E; Wu S
    Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
    Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
    BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.